Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sage Therapeutics scraps Alzheimer’s drug development
Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment
Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive
2h
SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Narrowed Success Prospects
SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
pharmaphorum
13h
Sage takes another hit as Alzheimer's drug is canned
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
FierceBiotech
1d
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
2h
SAGE Therapeutics (SAGE) Gets a Hold from TD Cowen
TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...
19h
Sage the Gemini Accused of Sexually Assaulting a Woman in New Police Report
Last month, TikTok user Hana Katana accused the rapper of sexual assaulting her at Chris Brown's home when she was 18.
BioSpace
1d
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
The Source Magazine
4h
Sage The Gemini Accused of Sexual Assault at Chris Brown’s LA Home
Rapper Sage the Gemini, best known for his hits “Red Nose” and “Gas Pedal,” is facing serious allegations of sexual assault stemming from an incident that allegedly took place at Chris Brown’s Los ...
The Daily News of Newburyport
6h
Purple Sage Studio open studio sale later this month
Twice a year Purple Sage Pottery opens its doors for an open studio sale. Sixteen local potters will offer a variety of ...
23h
Rapper Sage the Gemini accused of sexual assault at Chris Brown’s home
A woman has claimed that “Gas Pedal” rapper Sage the Gemini sexually assaulted her inside Chris Brown’s home in Los Angeles.
8h
SAGE Therapeutics: Downgrade to Sell Amid Pipeline Setbacks and Reduced Price Target
Bank of America Securities analyst Tazeen Ahmad has reiterated their bearish stance on SAGE stock, giving a Sell rating on October 4. Tazeen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Sexual assault
Alzheimer's disease
Chris Brown
dalzanemdor
LIGHTWAVE
Feedback